We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Audentes Therapeutics, Inc. (“Audentes” or the “Company”) (NASDAQ: BOLD) to Astellas Pharma Inc. (“Astellas”). Under the terms of the transaction, Astellas will acquire Audentes at a price of $60.00 per share in cash.
The investigation of the Audentes merger concerns whether the Board of Audentes breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction and whether Astellas is underpaying for Audentes shares, thus unlawfully harming Audentes shareholders.
To receive more information, please fill out the form.